Healthcare Market Research Company in Egypt

    BioNixus is a healthcare market research firm in Cairo and across Egypt, designing and executing primary studies for healthcare and pharma teams launching products across Egypt's public, private, and out-of-pocket channels. Our healthcare market research agency covers HCP insight, KOL mapping, patient journey studies, and payer access research — purpose-built for Egypt's EDA-regulated, UHI-expanding health system.

    Looking for pharmaceutical-specific research? Pharmaceutical market research company in Egypt covers EDA registration, tender, and access evidence. For all-industry research, see Market research in Egypt.

    Best healthcare market research company in Egypt

    BioNixus is a leading healthcare market research company in Egypt, specialising in HCP surveys, KOL mapping, and market access research aligned with EDA (Egyptian Drug Authority) requirements and Egypt's expanding universal health insurance (UHI) system.

    • HCP and Physician SurveysBilingual (English/Arabic) interviews and surveys across physicians, pharmacists, and nurses in Cairo, Alexandria, and regional Egypt.
    • KOL Mapping and Influence AnalysisIdentify key opinion leaders and map influence networks by therapy area across Egyptian academic and clinical health systems.
    • Market Access and Pricing ResearchMinistry of Health tender analysis, UHI coverage mapping, and willingness-to-pay studies across Egyptian public and private healthcare channels.

    BioNixus delivers primary healthcare market research in Egypt with EDA-aligned methodologies across public, private, and out-of-pocket health systems.

    What we research: therapeutic areas and segments in Egypt

    Oncology & hematology

    Cairo and Alexandria oncology centre KOL mapping and treatment-pathway research across public and private hospital networks

    Diabetes & metabolic disease

    Treatment algorithm research, GLP-1/insulin adoption, and payer coverage across MOH tender and private insurance channels

    Cardiovascular disease

    High-volume chronic therapy research covering antihypertensives, statins, and anticoagulant prescribing behaviour

    Generic substitution & pricing

    Price sensitivity, brand loyalty, and generic substitution attitudes central to Egypt's high-generic-penetration market

    Medical devices & diagnostics

    Device adoption, procurement committee behaviour, and health technology assessment research for Egyptian hospital tenders

    Infectious disease & vaccines

    MOH vaccination programme awareness, uptake drivers, and hesitancy research across Egyptian population segments

    Research audiences: who we reach in Egypt

    HCPs — physicians and specialists

    Prescribing oncologists, diabetologists, cardiologists, and primary care physicians across Cairo, Alexandria, and regional Egyptian hospitals and clinics.

    KOLs — key opinion leaders

    Egyptian academic and clinical thought leaders in target therapy areas, mapped across public university hospital and private specialist networks.

    Patients and caregivers

    Patient journey studies, quality-of-life research, and support-program needs assessment — conducted with ethics-appropriate consent and Arabic-language materials.

    Payers and procurement committees

    Ministry of Health tender committees, UHI coverage administrators, insurer medical directors, and hospital procurement leads who shape real-world access.

    Pharmacists

    Community and hospital pharmacist attitudes, dispensing behaviour, generic substitution practices, and patient counselling patterns across Egyptian retail and institutional pharmacy.

    Healthcare research methodology

    Every BioNixus Egypt healthcare study begins with a single commercial or access decision — launch sequencing, payer narrative, KOL prioritization, or competitive positioning. Instruments, sample frames, and analysis plans are designed backward from that decision.

    We combine quantitative rigor (structured HCP surveys, segmentation, adoption models) with qualitative depth (in-depth interviews, virtual advisory boards, paired physician-payer modules) so leadership sees both the metric and the reason behind it.

    Fieldwork follows healthcare research standards: screened and verified respondents, documented consent, de-identified reporting, and bilingual materials reviewed for clinical accuracy before launch. Arabic and English execution is standard across all Egypt programs.

    For advisory board and real-world evidence (RWE) programs, BioNixus designs sessions compatible with EDA regulatory frameworks — ensuring findings can support access dossiers and reimbursement submissions.

    Regulatory and market access depth: EDA and universal health insurance

    Egypt's healthcare market research must account for a dual-channel structure: the Egyptian Drug Authority (EDA) governs drug and device registration, while public volume flows through Ministry of Health tender procurement and the progressively expanding universal health insurance (UHI) system alongside the Hayah Karima national development initiative. BioNixus designs studies that reflect this evolving public-channel structure rather than treating Egypt's healthcare market as static.

    Parallel to the public system, private hospitals, insurers, and out-of-pocket pharmacy purchases serve urban and higher-income segments at different price points and formulary logic. Research programs map both the public access pathway (EDA registration, MOH tender listing, UHI coverage timing) and the private commercial layer (insurer medical policies, hospital committee behaviour, pharmacy substitution).

    Egypt is North Africa's largest pharmaceutical market by population — roughly 109 million people — with a strong domestic manufacturing base that also serves as a regional export hub for Africa. BioNixus KOL maps and HCP studies segment by channel, specialty, and region so you target influence and volume where they actually sit for your therapy area.

    Why pharmaceutical teams choose BioNixus in Egypt

    • ✓Specialist in pharma and healthcare research — not a generalist panel company running healthcare as a sideline
    • ✓Verified Egyptian physician and specialist panels across Cairo, Alexandria, and regional markets
    • ✓Bilingual Arabic–English fieldwork with culturally validated instruments
    • ✓Deep EDA and UHI regulatory context built into study design
    • ✓Dual quantitative and qualitative capability in one team — no subcontracting
    • ✓Real-world evidence and advisory board program design compatible with Egyptian access submissions
    • ✓17+ countries, 127+ projects delivered across MENA and beyond
    • ✓Cairo-based execution with regional MENA fieldwork reach

    Related Egypt healthcare research resources

    Top pharmaceutical companies in EgyptEgypt pharmaceutical market researchAll-industry market research in EgyptEgypt healthcare market research hubPharma fieldwork in EgyptTop market research companies in Egypt (2026)

    FAQs

    What are the best healthcare market research firms in Egypt?

    BioNixus is a leading healthcare market research firm in Egypt, delivering HCP, KOL, patient, and payer studies aligned with Egyptian Drug Authority (EDA) requirements and Egypt's expanding universal health insurance (UHI) system. We combine primary research depth with Cairo-based fieldwork and bilingual Arabic-English execution.

    What does a healthcare market research agency in Egypt typically do?

    A healthcare market research agency in Egypt designs and executes studies covering physician attitudes, public tender and UHI access, patient journeys, and competitive landscape for pharmaceutical and medical device companies operating across Egypt's public and private healthcare channels.

    How does Egypt's universal health insurance (UHI) system affect healthcare research?

    Egypt's UHI rollout is progressively expanding public coverage alongside the existing Ministry of Health tender system and Hayah Karima initiative. Research programs must track how UHI expansion shifts volume from out-of-pocket and private-insurance channels into publicly reimbursed pathways, since formulary and pricing dynamics differ materially between them.

    What therapeutic areas do healthcare market research companies in Egypt cover?

    BioNixus covers oncology, diabetes and metabolic disease, cardiovascular, infectious disease, generics substitution research, medical devices, and diagnostics across Egypt's public and private healthcare systems.

    Can BioNixus recruit HCPs and KOLs in Egypt?

    Yes. We maintain physician and specialist panels across Cairo, Alexandria, and regional Egyptian markets. For scarce specialties or KOL-level access, we extend to hospital networks, medical syndicate directories, and academic centre relationships with appropriate recruitment lead time.

    What is the typical timeline for healthcare market research in Egypt?

    Focused HCP surveys typically complete in 3-4 weeks. Full mixed-method programs including public tender/UHI access mapping and payer depth modules typically run 5-8 weeks depending on therapy scarcity and ethics review requirements.

    Does healthcare market research in Egypt cover generics and local manufacturing dynamics?

    Yes. Egypt has one of the largest domestic pharmaceutical manufacturing bases in the region, supplying a high share of local medicine demand and serving as a regional export hub for Africa. BioNixus research covers generic substitution attitudes, price sensitivity, and brand loyalty dynamics that are central to the Egyptian market.

    Where can I find general (non-healthcare) market research in Egypt?

    See our Market Research in Egypt page for all-industry research spanning FMCG, retail, BFSI, telecom, real estate, and technology.

    Request a proposal